Blue Flower

Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

Dear Madam, Dear Sir

On behalf of the entire NOXXON team I am pleased to welcome you to this section of our website. NOXXON is a European biopharmaceutical company developing anticancer treatments targeting the tumor microenvironment quoted on Euronext Growth - Paris, formerly Alternext,.

Our goal is to significantly improve cancer therapies, in particular immuno-oncology approaches, such as checkpoint inhibitors, but also standard therapies such as chemo- and radio-therapy. Patient recruitment is nearly complete in the ongoing Phase 1/2 trial of our lead product, NOX-A12, in combination with the immunotherapy agent from Merck & Co./MSD in patients with metastatic colorectal (10 patients) or metastatic pancreatic cancer (10 patients) at the National Center for Tumor diseases in Heidelberg, Germany.

Analysis of preliminary interim data from this trial confirms the previously reported and published safety and tolerance profile of NOX-A12, with no serious adverse events related to treatment with NOX-A12 monotherapy. In addition, data from the first twelve patients with available paired biopsies have been analyzed and suggest that NOX-A12 is able to penetrate tumor tissue, neutralize its target, and trigger a signature consistent with an immuno-stimulatory cytotoxic /Th1 type response. We are encouraged by the feedback from the clinicians who are very committed to this study and we are working diligently to ensure that we will be able to report top-line data from the entire group of patients in 2018.

We are pleased to count you amongst our shareholders at this crucial phase in our development at a company as we look to increase the therapeutic impact of immunotherapy agents by combining them with NOX-A12 and work to advance our other clinical stage agent further in development.

Best regards

Aram Mangasarian, PhD
Chief Executive Officer

• Download the initiation report on NOXXON by Aurgalys
➥ See latest update note from Aurgalys here
• Download the re-initiation report (Dec 2018) on NOXXON by Invest Securities


Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017